Diabetes and atrial fibrillation are just some of the factors that can increase a patient's risk of being hospitalized for heart failure within one year of undergoing a successful TAVR procedure.

Could wearables help AFib patients take fewer blood-thinning medications and reduce their risk of stroke? The team behind a new seven-year analysis hopes to find out. 

Researchers have shared an updated analysis of the SMART-CHOICE study, focusing on major adverse cardiac and cerebrovascular events—as well as bleeding events—among PCI patients after three years. 

"By imposing a 35%-42% cut, [CMS] has essentially created a scenario where it is going to destroy electrophysiology as a field," explained Dhanunjaya "DJ" Lakkireddy, MD.

We spoke to executives from some of healthcare's most prominent vendors to find out what challenges are on their radar in 2022 and beyond. 

Interview with Dhanunjaya Lakkireddy, MD, executive medical director for the Kansas City Heart Rhythm Institute at HCA Midwest Health, on recent advances in electrophysiology (EP) ablation and mapping systems to improve outcomes in atrial fibrillation therapy.

“Our ultimate goal is to prevent strokes," one Mayo Clinic electrophysiologist said. "I believe the current study has brought us one step closer.”

The recall is due to a malfunction risk that could, if not handled properly, cause the pump to stop working for a long period of time. This could lead to a serious injury or death, according to the recall. 

BIOTRONIK has announced a new partnership with AliveCor.

If researchers can find ways to prevent AKI after TAVR, it could help decrease the risk of poor outcomes in more ways than one.